EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

doi:10.3748/wjg.121829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 43

This Article

(1)

(2)

(0)

(27)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 21, 2026; 32(43): 121829
Published online Nov 21, 2026. doi: 10.3748/wjg.121829

Table 1 Clinical characteristics of patients with colonic adenocarcinoma from colonic adenocarcinoma clinical specimens, n (%)

Characteristics
Tumor location
Right	40 (57.1)
Left	30 (42.9)
Age (years)
≤ 65	35 (50.0)
> 65	35 (50.0)
Sex
Male	37 (52.9)
Female	33 (47.1)
T stage
T1	5 (7.1)
T2	10 (14.3)
T3	45 (64.3)
T4	10 (14.3)
N stage
N0	41 (58.6)
N1	21 (30.0)
N2	8 (11.4)
M stage
M0	59 (84.3)
M1	11 (15.7)
Grade
Well differentiated	13 (18.6)
Moderately differentiated	45 (64.3)
Poorly differentiated	12 (17.1)
Overall survival
Alive	48 (68.6)
Dead	22 (31.4)

Full Size Table

Citation: Li WX, Shi QZ, Mu YH, Li CL, Khan S, Zhao WC, Han N. EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma. World J Gastroenterol 2026; 32(43): 121829
URL: https://www.wjgnet.com/1007-9327/full/v32/i43/121829.htm
DOI: https://dx.doi.org/10.3748/wjg.121829

Li WX, Shi QZ, Mu YH, Li CL, Khan S, Zhao WC, Han N. EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma. World J Gastroenterol 2026; 32(43): 121829 [DOI: 10.3748/wjg.121829]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.